ASCO Abstract Preview: ImClone, Genentech

---

Array BioPharma ARRY:

Abstract No. 4114: AZD6244 (ARRY-142886) vs. capecitabine in patients with metastatic colorectal cancer who have failed prior chemotherapy.

Abstract No. 9033: AZD6244 (ARRY-142886) vs. temozolomide in patients with advanced melanoma; an open-label, randomized, multicenter, phase II study.

Abstract No. 8029: Efficacy and safety of AZD6244 (ARRY-142886) as second/third-line treatment of patients with advanced non-small-cell lung cancer.

---

Avant Immunotherapeutics AVAN:

Abstract No. 2011: Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM.

---

Celgene CELG:

Abstract No. 8509: International study of lenalidomide in relapsed/refractory aggressive non-Hodgkin's lymphoma.

Abstract No. 8504: Randomized trial of lenalidomide plus high-dose dexamethasone vs. lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma (E4A03), a trial coordinated by the Eastern Cooperative Oncology Group; Analysis of response and survival.

---

Cell Genesys CEGE:

Abstract No. 5146: Expanded phase I combination trial of GVAX immunotherapy for prostate cancer and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHPRC).

---

Cougar Biotechnology CGRB:

Abstract No. 5019: Abiraterone acetate and prednisone in patients with progressive metastatic castration resistant prostate cancer after failure of docetaxel-based chemotherapy.

Abstract No. 5005: Anti-tumor activity of abiraterone acetate (AA), a CYP17 inhibitor of androgen synthesis, in chemotherapy naive and docetaxel pre-treated castration resistant prostate cancer.

---

Curis CRIS:

Abstract No. 3516: A first-in-human, first-in-class, phase I study of systemic Hedgehog pathway antagonist, GDC-0449, in patients with advanced solid tumors.